Gary Morrow
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Gary Morrow sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Gary Morrow: 16 sponsored US clinical trials, none currently recruiting.
Gary Morrow sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 6 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sleep Disorders, with 1 trials.
Top-decile sponsor footprint
Gary Morrow ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
NCT02556632
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
NCT02352779
Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trials
NCT02054715
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
NCT02002533
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
NCT00924651
Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)
NCT00602420
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
NCT00471445
Yoga in Treating Sleep Disturbance in Cancer Survivors
NCT00397930
Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
NCT00040742
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
NCT00031837
Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer
NCT00042848
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
NCT00022074
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
NCT00020657
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
NCT00003817
Group Therapy Compared With Educational Materials in Patients With Prostate Cancer
NCT00002848
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
NCT00002850
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 6 |
How the Gary Morrow archive is shaped
16 indexed studies, none listed as recruiting (0% open); 15 completed (94%).
Phase mix: 6 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Sleep Disorders (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Gary Morrow: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Gary Morrow sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Gary Morrow page
16 registered trials is a research-attention snapshot, not an endorsement of Gary Morrow or any single study.
- None of Gary Morrow's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sleep Disorders is the condition Gary Morrow studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sleep Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gary Morrow pipeline card: 16 registered trials from official public datasets.Report a data error.